Revolutionizing Pharmaceuticals: The Rise of Artificial Intelligence in Drug Discovery.

1
Revolutionizing Pharmaceuticals The Rise of
Artificial Intelligence in Drug Discovery.
Global Artificial Intelligence (AI) in Drug
Discovery Market will expand at 30.1 CAGR from
2023 to 2032, driven by the growing number of
cross-industry collaborations and partnerships.
The convergence of pharmaceutical expertise with
AI-driven technologies enables faster and more
efficient drug discovery processes.
Collaborations facilitate the integration of AI
algorithms into drug research, accelerating the
identification of potential compounds and
reducing development timelines. This synergy
between different sectors fuels innovation,
driving the growth of the AI in drug discovery
industry.
2
Quoting an instance, in October 2023, Evozyn
revealed the completion of an 81 million Series
B funding round dedicated to supporting the
advancement of its generative AI-powered drug
discovery platform and product development
efforts. This development comes on the heels of a
productive partnership with NVIDIA earlier in
2023, during which the two companies jointly
created an innovative AI model capable of
designing therapeutic proteins. The overall AI in
drug discovery market is categorized based on
component, technology, application, therapeutic
area, end-use, and region. The services segment
could garner commendable gains throughout
2023-2032. AI in drug discovery market is in high
demand due to their ability to significantly
expedite the drug development process. AI
algorithms can analyze vast datasets, predict
potential drug candidates, and optimize molecular
structures with remarkable speed and precision.
This not only reduces research and development
timelines but also lowers costs. With the need
for faster and more efficient drug discovery
solutions, the demand for AI services in this
sector continues to grow.
3
AI in drug discovery market and services could
experience surging demand in preclinical testing
applications by 2032 because they enhance
accuracy and efficiency. AI-powered algorithms
can swiftly analyze complex biological and
chemical data, aiding in the identification of
promising drug candidates and predicting their
behavior in preclinical testing. This reduces the
need for extensive laboratory experiments,
accelerates the drug development timeline, and
ultimately lowers costs, making AI indispensable
in the preclinical testing phase of drug
discovery. Europe AI in drug discovery market
could exhibit noteworthy CAGR between 2023-2032.
Europe boasts a strong pharmaceutical sector and
is investing significantly in AI research.
According to EFPIA's Annual Report for 2022, the
research-based pharmaceutical industry in Europe
has seen substantial growth in production value,
rising from 127.5 billion euros in 2000 to 300
billion euros in 2021. Equally noteworthy is the
remarkable increase in exports, which surged from
90.9 billion euros to 565 billion euros during
the same timeframe. In 2021, imports accounted
for 390 billion euros, resulting in a positive
trade balance of 175 billion euros. Regulatory
support for innovation and partnerships between
academia, startups, and established
pharmaceutical companies fosters AI adoption.
Additionally, the need for more efficient drug
development processes to combat diseases like
COVID-19 accelerates the demand for AI in drug
discovery market across the European region.